Skip to main content
    N

    Nuwellis Inc (NUWE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.90
    -0.13 (-2.58%)

    Market Cap: $2.65M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Nuwellis Inc (NUWE) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Nuwellis (NUWE) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Nuwellis reported EPS of -$5.81, above the -$122.85 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    28%(11/39)
    Avg Surprise
    -5.62%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.34
    RangeN/A
    3 analysts
    Revenue Consensus
    $2.60M
    Range$2.49M - $2.67M
    3 analysts

    Next Report

    NUWE has an expected report date of Mar 8, 2027.

    NUWE Earnings Call

    The latest NUWE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, NUWE beat 11, missed 10 and matched 18. Revenue for the quarter ended Sep 30, 2026 was $2.21M, down 0.5% from $2.22M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$5.81-$122.85N/A+95.27%Beat-129.6%10 up, 1 downNov 12, 2026$2.21M
    Jun 30, 2026-$26.64-$23.80N/A-11.93%MissN/A10 up, 1 downAug 13, 2026$1.97M
    Mar 31, 2026-$73.15-$35.00N/A-109.00%MissN/A11 up, 0 downMay 12, 2026$2.40M
    Dec 31, 2025-$1.50-$1.56N/A+3.85%BeatN/AN/AN/AMar 10, 2026$2.42M
    Sep 30, 2025$19.60-$602.70N/A+103.25%Beat-99.2%N/A0 up, 0 downNov 12, 2025$2.22M
    Jun 30, 2025-$2,134.65-$661.50N/A-222.70%MissN/AN/A0 up, 0 downAug 14, 2025$1.73M
    Mar 31, 2025-$1,014.30-$661.50N/A-53.33%MissN/AN/A0 up, 0 downMay 13, 2025$1.90M
    Dec 31, 2024-$0.44-$0.43N/A-2.33%MissN/AN/A0 up, 0 downMar 11, 2025$2.32M
    Sep 30, 2024$2,557.81-$1,881.60-$2,468.12 - -$1,292.82+235.94%BeatN/A20 up, 0 downNov 11, 2024$2.37M
    Jun 30, 2024-$27,709.56-$12,120.18-$13,941.94 - -$10,283.83-128.62%MissN/A20 up, 0 downAug 13, 2024$2.19M
    Mar 31, 2024-$0.60-$1.06-$1.06 - -$1.06+43.40%BeatN/A10 up, 0 downMay 7, 2024$1.86M
    Dec 31, 2023-$115,248.35-$71,515.71-$113,522.84 - -$45,717.34-61.15%MissN/A30 up, 0 downMar 5, 2024$2.55M
    Sep 30, 2023-$93,124.78-$160,181.48-$166,431.68 - -$154,103.40+41.86%BeatN/A30 up, 0 downNov 7, 2023$2.41M
    Jun 30, 2023-$187,793.06-$207,001.12-$224,477.29 - -$181,328.34+9.28%BeatN/A30 up, 0 downAug 8, 2023$2.08M
    Mar 31, 2023-$261,820.06-$430,123.29N/A+39.13%BeatN/A30 up, 0 downMay 9, 2023$1.83M
    Dec 31, 2022-$5.00-$17.09-$36.00 - -$13.31+70.74%BeatN/A20 up, 0 downFeb 28, 2023$2.34M
    Sep 30, 2022-$1,000,000.00-$1,000,000.00-$2,157,447.65 - -$667,781.420.00%In lineN/A31 up, 0 downNov 8, 2022$2.06M
    Jun 30, 2022-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/A0 up, 0 downAug 9, 2022$2.21M
    Mar 31, 2022-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A32 up, 0 downMay 10, 2022$1.93M
    Dec 31, 2021-$41.00-$47.67-$51.00 - -$41.00+13.99%BeatN/A30 up, 0 downMar 1, 2022$1.64M
    Sep 30, 2021-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A3N/ANov 9, 2021$1.85M
    Jun 30, 2021-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AAug 10, 2021$2.51M
    Mar 31, 2021-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AMay 11, 2021$1.92M
    Dec 31, 2020-$157.00-$191.00N/A+17.80%BeatN/AN/AN/AMar 2, 2021$2.04M
    Sep 30, 2020-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/ANov 10, 2020$1.90M
    Jun 30, 2020-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AAug 4, 2020$1.86M
    Mar 31, 2020-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AMay 12, 2020$1.63M
    Dec 31, 2019-$3,360.00-$2,400.00N/A-40.00%MissN/AN/AN/AMar 3, 2020$1.37M
    Sep 30, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/ANov 5, 2019$1.25M
    Jun 30, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AAug 6, 2019$1.68M
    Mar 31, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AMay 7, 2019$1.22M
    Dec 31, 2018-$25,110.00-$22,680.00N/A-10.71%MissN/AN/AN/AFeb 20, 2019$1.50M
    Sep 30, 2018-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/ANov 6, 2018$1.36M
    Jun 30, 2018-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AAug 7, 2018$1.10M
    Mar 31, 2018-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AMay 8, 2018$1.04M
    Dec 31, 2017-$187,320.00-$52,920.00N/A-253.97%MissN/AN/AN/AMar 20, 2018$831000
    Sep 30, 2017-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AOct 31, 2017$957000
    Jun 30, 2017-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AAug 8, 2017$864000
    Mar 31, 2017-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AMay 9, 2017$901000
    Dec 31, 2016-$38,976.00N/AN/AN/AN/AN/AN/AN/AMar 2, 2017$746000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3,130.85, after -$25,152.79 the year before. It was -$3,038,976.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3,130.85N/A
    Dec 31, 2024-$25,152.79N/A
    Dec 31, 2023-$657,986.25N/A
    Dec 31, 2022-$3,000,005.00N/A
    Dec 31, 2021-$3,000,041.00N/A
    Dec 31, 2020-$3,000,157.00N/A
    Dec 31, 2019-$3,003,360.00N/A
    Dec 31, 2018-$3,025,110.00N/A
    Dec 31, 2017-$3,187,320.00N/A
    Dec 31, 2016-$3,038,976.00N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,200 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,1774
    2026Q1Mar 31, 20262,5125
    2025Q4Dec 31, 20252,8235
    2025Q2Jun 30, 20251,7585
    2025Q1Mar 31, 20252,4815
    2024Q3Sep 30, 20243,1357
    2024Q2Jun 30, 20242,7196

    2026Q3 Earnings Call

    Opening remarks

    Leah McMullen Director of Communications Thank you, operator. Thank you for joining today's conference call to discuss Nuwellis' corporate developments and financial results for the third quarter of 2026. Joining me today are Mike McCormick, Nuwellis' President and Chief Executive Officer, and Carisa Schultz, Chief Financial Officer. Earlier today, Nuwellis released its third quarter 2026 financial results. If you have not received the earnings release, please visit the Investors page of the company's website. During this conference call, the company will be making forward-looking statements. All forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends, as well as our estimated results or performance, are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon currently available information, and the company assumes no obligation to update these statements. Accordingly, you should not place any undue reliance on these statements. Please refer to the cautionary statements and discussion of risks in the company's filings with the Securities and Exchange Commission, including the latest 10-K. With that, I would now like to turn the call over to Mike McCormick, Nuwellis' CEO.

    Michael McCormick President and Chief Executive Officer Thank you, Leah, and good morning, everyone. On our last conference call, I outlined three priorities for Nuwellis. First, to increase Aquadex utilization and recurring circuit revenue; second, to build on our strong position in pediatrics and expand our presence in adult critical care; and third, to strategically broaden our cardiorenal platform through technologies and collaborations that complement Aquadex and leverage our existing customer relationships. From a financial standpoint, we made meaningful progress in the quarter, improving our operating performance. Third-quarter gross margin expanded 430 basis points, while operating expenses declined 13% year over year, resulting in a 24% improvement in operating loss. These results reflect our continued focus on disciplined spending, improved operating efficiency, and directing resources toward the highest-priority growth initiatives. The expansion of our installed base remains one of our most important indicators of our commercial progress. During the first nine months of 2026, we sold 32 Aquadex consoles. That's an 88% increase compared with 17 consoles during the same period last year. In the third quarter, we sold eight consoles compared with 12 in the prior-year quarter. Every console added to our installed base expands the opportunity for recurring circuit revenue, and our teams remain focused on increasing utilization across our existing hospital customers. We had a strong first half of 2026.

    Frequently Asked Questions About NUWE

    When is Nuwellis's next earnings date?

    Nuwellis's next earnings report is expected for Mar 8, 2027.

    Did NUWE beat earnings estimates last quarter?

    Yes. Nuwellis reported EPS of -$5.81 for the quarter ended Sep 30, 2026, above the -$122.85 estimate, a 95.27% surprise.

    What EPS do analysts expect from NUWE next quarter?

    The consensus EPS estimate for Nuwellis for the quarter ending Dec 31, 2026 is -$0.34 from 3 analysts.

    How often does NUWE beat earnings estimates?

    Nuwellis beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -24.62%.